Posted by Michael Wonder on 15 Aug 2018
Eli Lilly is defying California law with its insulin price hikes. A law maker calls its actions ‘offensive'.
9 August 2018 - Seven months after a controversial California law took effect requiring advance notice of planned price increases for prescription drugs, many pharmaceutical companies appear to be in compliance.
But not Eli Lilly.
The Indianapolis-based drug maker — one of the largest producers of insulin — has been under fire from consumer advocates for jacking up prices on its lifesaving diabetes medication. And the company has chosen not to follow the California law, which requires it not only to disclose but justify significant price hikes to drug purchasers.
